Spring Bank successfully completed a Phase 1 SAD/MAD study of SB 9200 in healthy HCV infected patients in 2014 looking at safety and antiviral efficacy of single oral doses of SB 9200 between 100 mg and 900 mg once a day. The data from this Phase 1 study was presented at the 2015 EASL meeting.
In June 2016, we initiated a Phase 2 clinical trial of SB 9200 in non-cirrhotic patients with chronic Hepatitis B virus (HBV) to explore both monotherapy and combination therapy with a direct-acting antiviral (DAA). In May 2017, we reported top-line results from the initial 25mg cohort of the Phase 2a segment of the Phase 2 clinical trial of SB 9200, which we refer to as the ACHIEVE trial. Click here for additional information about these results.